A股異動 | 江蘇索普(600746.SH)漲逾4% “烏雞變鳳凰”前三季度淨利暴增39倍
格隆匯10月11日丨江蘇索普(600746.SH)漲逾4%,報18.78元,總市值219億元。10月8日晚,江蘇索普公吿稱,公司預計前三季度實現淨利潤21.30億至21.80億,同比暴增超39倍。這對於多年處於虧損邊緣的江蘇索普來説,2021年公司從“烏雞”變成了“鳳凰”,包括華安、易方達、諾安等頂流基金在二季度紛紛主動加倉,私募、QFII和券商也相繼入場投資。 公司今年前三季度的業績增長主要來自醋酸價格上漲,去年上半年的時候 ,華東地區的醋酸價格每噸在2500-2600元,現在已經漲到9000元左右。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.